Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 254)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.721
Gesamt: 345.721
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: RXK3
1,4820
EUR
-2,50 %
-0,0380 EUR
Letzter Kurs 12:46:47 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8450 | +163,57 | |
| 0,5470 | +20,09 | |
| 384,00 | +20,00 | |
| 5,9050 | +17,86 | |
| 111,15 | +16,77 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 71,33 | -33,92 | |
| 3,6400 | -38,62 | |
| 1.160,00 | -42,00 |
Beitrag zu dieser Diskussion schreiben
Feedback
Danke Aurum für den Beitrag. Da war mein Beitrag schon geschrieben. Schön zu lesen das galena auf die Anschuldigungen von unserem Herrn Geröllheimer reagiert hat. Und das was sie dort sagen deckt sich auch mit meiner Meinung wie ich bereits geschrieben habe. Es ist wohl mal wieder viel Lärm um Nichts. Die Vortschritte von galena stehen für sich. Selbst wenn an den Anschuldigungen der bezahlten Kolumnisten was dran wäre würde das nichts an den langfristigen Aussichten ändern. Wäre zwar nicht die feine englische Art, aber was solls. Nun ja. Diese Stellungnahme bestärkt mich in meinem Investment. Bin sicher wir sehen hier bald wieder bessere Kurse.
Allen Investierten noch viel Glück.
Allen Investierten noch viel Glück.
Das denke ich auch
Gestern eingestiegen weil ich dachte die drei tage sinkflug sind durch, hab aber das lange wochenende in us unterschätzt.
Gestern eingestiegen weil ich dachte die drei tage sinkflug sind durch, hab aber das lange wochenende in us unterschätzt.
Also meiner Meinung nach ist die Pipeline von galena top. Da ändern auch die Gerüchte nichts daran. Ob an den Gerüchten was dran ist muss jeder für sich selbst entscheiden. Da aber Herr Feuerstein mal wieder der Stein des Anstosses war ist meiner Meinung nach nicht all zu viel davon zu glauben. Der führt wohl grad einen Kleinkrieg gegen diverse Biotechs.
Ich bin weiterhin von galena überzeugt und denke das wir nächsten Dienstag bereits wieder ins Plus drehen. Naja viel weiter runter geht ja auch gar nicht mehr. Der Schlusskurs lässt jedenfalls darauf schließen. Obwohl ich nicht weiß wie hoch die shortquote heute war und wieviele davon bereits heut nach 25% Minus bereits gecovert haben.
Ich hab auch zu teuer gekauft aber bleibe auf alle Fälle drin. Meiner Meinung nach werden wir noch viel Freude mit galena haben.
Ich bin weiterhin von galena überzeugt und denke das wir nächsten Dienstag bereits wieder ins Plus drehen. Naja viel weiter runter geht ja auch gar nicht mehr. Der Schlusskurs lässt jedenfalls darauf schließen. Obwohl ich nicht weiß wie hoch die shortquote heute war und wieviele davon bereits heut nach 25% Minus bereits gecovert haben.
Ich hab auch zu teuer gekauft aber bleibe auf alle Fälle drin. Meiner Meinung nach werden wir noch viel Freude mit galena haben.
Galena Biopharma Issues Letter to Shareholders
PORTLAND, Ore., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today issued a letter to its shareholders in response to recent media attention stemming from an article by TheStreet.com.
Dear Shareholders:
Due to the recent media attention on Galena Biopharma that we acknowledge is having an impact on investor confidence, we felt it necessary, as a service to our shareholders, to publicly respond to the discussions and set the record straight.
The genesis of this attention is due to a single reporter, Adam Feuerstein from TheStreet.com, who clearly has an agenda when it comes to Galena. This can be evidenced by his numerous, tabloid-like articles on the company that have appeared over the past three years and are sensational but largely devoid of true information. The article this week is just another in the line, which for us have become noise.
Mr. Feuerstein has never requested a meeting with the company to understand the details of our programs or the goals of the company. On the contrary, his requests for information are consistently accusatory and negative. As a result, we do not feel it is worthwhile to engage him or respond to other media outlets that serve to advance his agenda. However, we do recognize that you, our shareholders, deserve a direct response on the matters at hand.
The only facts in Mr. Feuerstein's most recent article that are remotely accurate are that Galena previously engaged the DreamTeamGroup and that insiders at the company, including me, divested shares in mid January. All other accusations in this article - as with his prior reporting on Galena - are specious and conveniently arranged to create controversy.
Over the past year, we have accomplished the following:
Acquired Abstral® (fentanyl) sublingual tablets, implemented a commercial team, launched the drug in October 2013, and currently have approximately 5% of the branded market after only four months of launch. Abstral is part of a class-wide Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program designed to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors with the use of TIRF medicines.
Initiated our RELIEF Patient Registry trial for Abstral.
Continued to progress our pivotal, Phase 3 PRESENT trial for NeuVax™ (nelipepimut-S) and added another commercial partnership with Dr. Reddy's in India.
Progressed enrollment with our Phase 2b combination trial with NeuVax and Herceptin® (trastuzumab).
Expanded our Intellectual Property with an issued patent for NeuVax in Europe.
Advanced our pipeline with the initiation of a Phase 2 trial with GALE-301, and we expect to report the Phase 1 data mid-year.
Broadened our portfolio into hematology with the acquisition of Mills Pharmaceuticals and anagrelide controlled release, now GALE-401.
These facts about Galena and our progress are indisputable and clearly demonstrate our dedication to the mission of transforming Galena into a leader in providing therapeutics across the entire cancer-care spectrum. My expectation is that 2014 will unlock additional opportunities that will undoubtedly serve to benefit all who are connected to the success of Galena - most importantly those individuals who are unfortunately confronted with the specter of cancer.
Looking ahead, I would hope that all investors, stakeholders and the media judge Galena on our ability to meet our publicly stated goals. Let success or failure be dictated by facts and data, not the questionable logic of a headline-seeking reporter.
We look forward to further updating you on our progress during our earnings conference call next month. Thank you for your continued interest in Galena.
Mark J. Ahn, Ph.D.
President & CEO
PORTLAND, Ore., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today issued a letter to its shareholders in response to recent media attention stemming from an article by TheStreet.com.
Dear Shareholders:
Due to the recent media attention on Galena Biopharma that we acknowledge is having an impact on investor confidence, we felt it necessary, as a service to our shareholders, to publicly respond to the discussions and set the record straight.
The genesis of this attention is due to a single reporter, Adam Feuerstein from TheStreet.com, who clearly has an agenda when it comes to Galena. This can be evidenced by his numerous, tabloid-like articles on the company that have appeared over the past three years and are sensational but largely devoid of true information. The article this week is just another in the line, which for us have become noise.
Mr. Feuerstein has never requested a meeting with the company to understand the details of our programs or the goals of the company. On the contrary, his requests for information are consistently accusatory and negative. As a result, we do not feel it is worthwhile to engage him or respond to other media outlets that serve to advance his agenda. However, we do recognize that you, our shareholders, deserve a direct response on the matters at hand.
The only facts in Mr. Feuerstein's most recent article that are remotely accurate are that Galena previously engaged the DreamTeamGroup and that insiders at the company, including me, divested shares in mid January. All other accusations in this article - as with his prior reporting on Galena - are specious and conveniently arranged to create controversy.
Over the past year, we have accomplished the following:
Acquired Abstral® (fentanyl) sublingual tablets, implemented a commercial team, launched the drug in October 2013, and currently have approximately 5% of the branded market after only four months of launch. Abstral is part of a class-wide Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program designed to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors with the use of TIRF medicines.
Initiated our RELIEF Patient Registry trial for Abstral.
Continued to progress our pivotal, Phase 3 PRESENT trial for NeuVax™ (nelipepimut-S) and added another commercial partnership with Dr. Reddy's in India.
Progressed enrollment with our Phase 2b combination trial with NeuVax and Herceptin® (trastuzumab).
Expanded our Intellectual Property with an issued patent for NeuVax in Europe.
Advanced our pipeline with the initiation of a Phase 2 trial with GALE-301, and we expect to report the Phase 1 data mid-year.
Broadened our portfolio into hematology with the acquisition of Mills Pharmaceuticals and anagrelide controlled release, now GALE-401.
These facts about Galena and our progress are indisputable and clearly demonstrate our dedication to the mission of transforming Galena into a leader in providing therapeutics across the entire cancer-care spectrum. My expectation is that 2014 will unlock additional opportunities that will undoubtedly serve to benefit all who are connected to the success of Galena - most importantly those individuals who are unfortunately confronted with the specter of cancer.
Looking ahead, I would hope that all investors, stakeholders and the media judge Galena on our ability to meet our publicly stated goals. Let success or failure be dictated by facts and data, not the questionable logic of a headline-seeking reporter.
We look forward to further updating you on our progress during our earnings conference call next month. Thank you for your continued interest in Galena.
Mark J. Ahn, Ph.D.
President & CEO
Trading Spotlight
Antwort auf Beitrag Nr.: 46.457.219 von lunatics am 14.02.14 20:26:17Was bedeutet 3/3???
So, habe heute auch nochmals zugelangt.
Habe wieder 3/3 GALE zu total EP 2.70.-
Habe wieder 3/3 GALE zu total EP 2.70.-
Und es geht UP!!!!
Aktuell schon wieder 3,70 $...
Aktuell schon wieder 3,70 $...
Ich meinte natürlich €. 
Ich gehe mal davon aus, dass wir heute über 3,80 $ schließen... Ist meistens so, dass sich eine Aktie nach solch einem Absturz zum Ende hin noch ein wenig erholt...
Gruß
Ich gehe mal davon aus, dass wir heute über 3,80 $ schließen... Ist meistens so, dass sich eine Aktie nach solch einem Absturz zum Ende hin noch ein wenig erholt...
Gruß
Also ich bin jetzt mit nem EK von 2,58 @ drin. Bin mal gespannt, ob wir am Montag oder heute Abend noch nen Rebound sehn...
Durchsuchen
